title: Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]).
abstract: The optimal blood pressure (BP) to prevent major adverse outcomes (death, myocardial infarction, and stroke) for patients with hypertension and coronary artery disease who have undergone previous revascularization is unknown but might be influenced by the type of revascularization procedure. We analyzed data from the INternational VErapamil SR-Trandolapril STudy, focusing on the relation between BP and the outcomes of 6,166 previously revascularized patients, using the 16,410 nonrevascularized patients as a reference group. The previous revascularization strategy consisted of coronary artery bypass grafting (CABG, 45.2%), percutaneous coronary intervention (PCI, 42.1%), or both (CABG+PCI, 12.8%). Patients who had undergone both CABG+PCI and CABG-only had a greater adverse outcome risk (adjusted hazard ratio 1.27% and 1.20%, 95% confidence interval 1.06 to 1.53 and 1.07 to 1.35, respectively). The risk was similar for PCI-only patients (adjusted hazard ratio 1.04, 95% confidence interval 0.92 to 1.19). The relations between the adjusted hazard ratio and on-treatment BP appeared J-shaped for each revascularization strategy, accentuated for PCI and diastolic BP (DBP), but excepting CABG only and DBP for which the relation was linear and positive. In conclusion, major adverse outcomes were more frequent in patients with coronary artery disease who had undergone previous CABG, with or without PCI, compared to those with previous PCI only. This likely reflected more severe vascular disease. The relation to systolic BP was J-shaped for each strategy. Among those patients with previous CABG only, the linear relation with DBP suggested that more complete revascularization might attenuate hypoperfusion at a low DBP. The management of BP might, therefore, require modification of targets according to the revascularization strategy to improve outcomes.
authors.affiliation: University of Florida College of Medicine, Gainesville, FL, USA. scott.denardo@medicine.ufl.edu
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Denardo
authors.forename: Franz H
authors.initials: FH
authors.lastname: Messerli
authors.forename: Efrain
authors.initials: E
authors.lastname: Gaxiola
authors.forename: Juan M
authors.initials: JM
authors.lastname: Aranda
authors.forename: Rhonda M
authors.initials: RM
authors.lastname: Cooper-Dehoff
authors.forename: Eileen M
authors.initials: EM
authors.lastname: Handberg
authors.forename: Yan
authors.initials: Y
authors.lastname: Gong
authors.forename: Annette
authors.initials: A
authors.lastname: Champion
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhou
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Pepine
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents